The Phase III FIND-CKD study was officially launched, and the clinical study of fenelrone was extended to patients with non-diabetic nephropathy

2021 Nian 9 Yue 20 days, Bayer announced the launch of FIND-CKD study, which was a multicenter, randomized, double-blind, placebo-controlled III clinical study investigated the addition of non-Nelly-one treatment guidelines recommend treatment based on Efficacy and safety of non- diabetic chronic kidney disease
.

The main purpose of the study is to prove that fennelrone can more effectively delay the progression of kidney disease in these patients than the addition of a placebo to the treatment recommended by the guidelines

2021 Nian 9 Yue 20 days, Bayer announced the launch of FIND-CKD study, which was a multicenter, randomized, double-blind, placebo-controlled III clinical study investigated the addition of non-Nelly-one treatment guidelines recommend treatment based on Efficacy and safety of non- diabetic chronic kidney disease

Chronic kidney disease ( CKD ) is a common and fatal disease that is not fully understood.

Professor Hiddo L.

Finelrone is a non-steroidal selective mineralocorticoid receptor antagonist, which has been shown in preclinical studies to block the harmful effects caused by excessive activation of mineralocorticoid receptors

Member of the Bayer prescription drug division of the Executive Committee, Head of R & D Christian Rommel Dr.

The Phase III FIND-CKD study will recruit more than 1,500 non-diabetic patients with chronic kidney disease, whose causes include hypertension and chronic glomerulonephritis (kidney inflammation).

This year 7 months, according to III clinical FIDELIO-DKD study in chronic nephropathy with 2 -positive results in patients with type non Connelly ketone to obtain marketing approval in the United States
.
Finnelrone has already submitted listing applications in many countries or regions such as the European Union and China, and it is in the review stage
.
Leave a message here